Do Talazoparib and Lynparib work the same?

Talazoparib (Talazoparib) and olaparib (Olaparib) both belong to a class of drugs known as PARP (polymerase-adenylate converting enzyme) inhibitors. Their mechanism of action is similar, by inhibiting the activity of PARP enzyme and blocking a branch of the DNA repair pathway, thereby causing DNA double-strand breaks in tumor cells, leading to tumor cell death.

Although talazopanib and olaparib have similar mechanisms of action, they have some differences in their molecular structures. These differences may lead to some differences in their pharmacodynamics, pharmacokinetics, drug resistance, etc. Talazopanib is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene-mutated HER2-negative locally advanced or metastatic breast cancer. It may also be used in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer. Olaparib is often used to treat cancer of the breast, ovary, fallopian tube, pancreas, prostate, or peritoneum (the membrane that covers the inside of the abdomen and covers some internal organs).

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).